Advances in the Field

July 13, 2017 – (Novartis) – "The panel's unanimous recommendation in favor of CTL019 moves us closer to potentially delivering the first-ever commercially approved CAR-T cell therapy to patients in need," said Bruno Strigini, CEO, Novartis Oncology. "We're very proud to be expanding new frontiers in cancer treatment by advancing immunocellular therapy for children and young adults with r/r B-cell ALL and other critically ill patients who have limited options. We look forward to working with the FDA as they complete their review." 
July 12, 2017 – (Cambridge Stem Cell Institute) – Scientists at the Cambridge Stem Cell Institute and the Sanger Institute have developed a new method for growing and transplanting artificial bile ducts that could in future be used to help treat liver disease in children, reducing the need for liver transplantation. 
May 31, 2017 – (Novartis) – The results, which will be presented at the upcoming 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO; abstract #7509; Monday, June 5, 1:15 PM CDT), that eight of nine evaluable patients had no signs of CLL in their bone marrow at three months.
January 12, 2017 – (TSRI) – “This cellular clock needs to be finely tuned to allow sufficient cell divisions to develop differentiated tissues and maintain renewable tissues in our body and, at the same time, to limit the proliferation of cancerous cells," said TSRI Associate Professor Eros Lazzerini Denchi, corresponding author of the new study.
January 17, 2017 – (Mass General) – Massachusetts General Hospital investigators have found new evidence that the tumor necrosis factor receptor type II may be a major target for immuno-oncology treatments, which induce a patient’s immune system to fight cancer.
January 16, 2017 – (Irvine Scientific) – Irvine Scientific announced the introduction of PRIME-XV T Cell CDM, the first commercially available chemically-defined, animal component-free medium for T cell culture. 
January 16, 2017 – (Fred Hutch) – Researchers have developed a new technique that allows them to examine huge amounts of information from a single cell or zoom out and see data patterns among thousands upon thousands of cells — all in a single experiment.

Pages